Virtual Clinical Trial Service Providers Market | Industry Analysis | Market Size

Virtual Clinical Trial Service Providers Market by Type of Therapeutic Area (Cardiovascular disorders, Infectious disorders, Metabolic disorders, Neurological disorders, Oncological disorders and Other disorders), End-Users (Small-sized players, Mid-sized players, Large players and Academia / Others), Phase of Development (Phase I, Phase II, Phase III and Phase IV), and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2020-2050

Lowest Price Guaranteed From USD 5,899
Published
January 2021
Pages
285
View Count
7066
Buy Now

Example Insights

Overview

The development of a novel molecular entity for pharmacological use, is not only complex but also cost intensive. It requires close to 10 years and over USD 2.5 billion in capital investment, for a prescription therapeutic to traverse from the bench to the market. It is worth highlighting that a significant proportion (40%) of the pharmaceutical R&D budget in the US is spent on clinical research, evaluating the safety and efficacy of novel therapeutic interventions in human subjects. Conducting clinical trials is also sophisticated and fraught with several challenges, including (but not limited to) patient recruitment-related concerns, inadequacies in handling (generation, logging and processing) clinical data, risk of failure (mostly owing to safety concerns and side effects of the drug / therapy being evaluated), and unforeseen delays leading to deterrence from predetermined completion timelines. In fact, retrospective studies have demonstrated that more than 90% of the time clinical trials are delayed due to the inability to either recruit or retain, the required number of patients. This has been shown to impose enormous financial burdens, ranging from USD 0.6 million (in the case of therapies with niche / limited applications) to USD 8 million per day (for a drug that is anticipated to be a blockbuster), on study sponsors. As indicated earlier, another notable concern in this space, is related to handling clinical data, which may be primarily attributed to inconsistencies and inefficiencies related to the recording and maintenance of electronic health records. Market analysts estimate that such, easily avoidable, data-related errors are responsible for USD 6 billion in losses incurred by the global pharmaceutical, each year. There is therefore, an exigent need to address this particular concern. In 2020, clinical trial conduct has been further impacted by the COVID-19 pandemic. In the initial months of the year, almost all available medical resources were directed towards treating the novel coronavirus infection and curtail its spread. As a result, several ongoing clinical studies were halted for considerable durations. Even now, as sponsors are gradually resuming their clinical trials, there are a number of restrictions and considerations that need to be taken into account, in order to ensure compliance to the new normal way of operating.

The concept of virtual clinical trials is one among the many developments in the modern pharmaceutical industry. Leveraging recent technological advances, several versatile solutions for remote patient engagement and monitoring, and medical data logging and analysis, have been developed. These have enabled therapy developers / trials sponsors to address some of the exigent concerns related to clinical trial conduct and offered the means to resume clinical research even during the ongoing pandemic. Presently, there are several companies offering a wide range of services and solutions for conducting and managing various aspects of clinical trials. This emerging approach to clinical research is deemed to have demonstrated the potential to disrupt, while also allowing sponsors / trial affiliates to become more patient centric. The fundamental requirements of a virtual clinical trial, include (but not limited to) dedicated software applications, remote patient health monitoring equipment and web-based social engagement platforms. Using such solutions, experts believe that sponsors can save up to 25% of the total capital investment in a trial. Moreover, such tools can be designed to optimize patient recruitment, reduce attrition and augment data analysis. Initiatives focused on conducting virtual trials and developing affiliated solutions have garnered the attention of several private and public investors, having accrued over USD 550 million in investment since 2014. With the growing preference for digitization of routine processes, coupled to the present need for social distancing, the virtual clinical trials market is likely to experience significant growth over the coming years.

Scope of the Report

The ‘Virtual Clinical Trial Service Providers Market, 2020-2050: Distribution by Type of Therapeutic Area (Cardiovascular Disorders, CNS Disorders, Infectious Disorders, Metabolic Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders, Trial Phases (Phase I, Phase II, Phase III and Phase IV), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)’ report features an extensive study of the current landscape and future opportunities of innovative clinical research platforms / solutions providers. Amongst other elements, the report features:

An overview of the current market landscape of companies offering solutions for virtual clinical trials, featuring information on year of establishment, geographical location, company size and types of services offered (study start-up, patient enrollment, drug logistics, data collection and analysis, and patient retention).
Brief profiles of companies offering solutions for virtual clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service / technology portfolio, recent developments and an informed future outlook.
A case study on the initiatives of big pharma players related to virtual clinical trials, offering insights on such clinical studies that have been conducted / planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain.
An analysis of the funding and investments made in the domain, in the period between 2014 and 2020 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, based on several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
An analysis of the partnerships and collaborations inked in the domain, in the period between 2014 and 2020 (till November), based on several parameters, such as year of partnership, type of partnership, application mentioned in agreement, target therapeutic area mentioned in the agreement, type of partner, most active players and geographical analysis.
A detailed study highlighting the key differences between traditional and virtual CROs and an elaborate road map, presenting the requirements for a traditional CRO to transition to a virtual CRO business model.
A brief case study highlighting the impact of COVID-19 pandemic on virtual clinical trial service providers market.
A detailed analysis of completed, ongoing and planned virtual clinical trials, based on multiple parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, target therapeutic area, trial design, top sponsor, geographical location of trial and enrolled patient population.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity of the market for virtual clinical trial services. Based on parameters, such as number of pre- or post-approval studies conducted annually, capital investments made in these studies, and the likely cost and time saving opportunities, we have provided an informed estimate of the likely evolution of the market for virtual clinical trials, for the period 2020-2050. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] trial phases (phase I, phase II, phase III and phase IV) and [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

Phillipe Lemmens (Chief Operating Officer, Andaman7)
Himanshu Verma (Founder and Chief Executive Officer, ConsilX) and Rajesh Jain (Co-Founder, ConsilX)
Greg Erman (President and Chief Executive Officer, EmpiraMed)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

Who are the leading virtual clinical trial service providers?
Which companies have raised significant capital in this domain?
How can traditional CRO transition to virtual CRO?
What factors are likely to influence the evolution of this upcoming market?
How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the virtual clinical trial service providers market, in the mid to long term.

Chapter 3 presents a general overview of the investment, in terms of time and cost, required for developing new healthcare products, along with information on other constraints associated with clinical research, including patient recruitment and retention, evolving regulatory standards and inefficient data handling. Further, it features a detailed outline on the various upcoming trends that are anticipated to play a crucial role in shaping the future of clinical trials, including increasing focus on patient centricity, precision medicine, real-world evidence, big data analytics, virtual clinical trials, innovative trial designs and blockchain-based platforms.

Chapter 4 provides a list of industry players that are actively involved in offering services for virtual clinical trials. The chapter presents analyses of these players based on year of establishment, geographical location, company size and types of services offered (study start-up, patient enrollment, drug logistics, data collection and analysis, and patient retention).

Chapter 5 features brief profiles of companies offering solutions for virtual clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service / technology portfolio, recent developments and an informed future outlook.

Chapter 6 is a case study on the initiatives of big pharma companies related to virtual clinical trials, offering insights on such clinical studies that have been conducted / planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain.

Chapter 7 provides an analysis of the funding and investments made in the domain, in the period between 2014 and 2020 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, based on several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 8 provides an analysis of the partnerships and collaborations inked in the domain, in the period between 2014 and 2020 (till November), based on several parameters, such as year of partnership, type of partnership, application mentioned in agreement, target therapeutic area mentioned in the agreement, year of partnership and type of partner, most active players and geographical analysis.

Chapter 9 provides a detailed study highlighting the key differences between traditional and virtual CROs and an elaborate road map, presenting the requirements for a traditional CRO to transition to a virtual CRO business model.

Chapter 10 provides an insightful discussion on the impact of COVID-19 pandemic on the virtual clinical trial service providers market.

Chapter 11 provides a detailed analysis of completed, ongoing and planned virtual clinical trials, based on multiple parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, target therapeutic area, trial design, top sponsor, geographical location of trial and enrolled patient population.

Chapter 12 provides an insightful opportunity analysis, estimating the existing market size and potential growth opportunities across service providers working in virtual clinical trials. Based on multiple parameters, such as number of studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2020-2050. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] trial phases (phase I, phase II, phase III and phase IV) and [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of virtual clinical trials service providers market.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. We have presented the details of our discussions with (in alphabetical order of company names) Phillipe Lemmens (Chief Operating Officer, Andaman7), Himanshu Verma (Founder and Chief Executive Officer, ConsilX), Rajesh Jain (Co-Founder, ConsilX) and Greg Erman (President and Chief Executive Officer, EmpiraMed).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Tables Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Existing Constraints in Clinical Research
3.2.1. Increasing Complexity and Cost of Trials
3.2.2. Evolving Regulatory Standards
3.2.3. Patient Recruitment and Retention Challenges
3.2.4. Data Handling-related Concerns

3.3. Virtual Clinical Trials
3.3.1. Key Aspects of Virtual Clinical Trials
3.3.1.1. Study Design
3.3.1.2. Patient Recruitment and Retention
3.3.1.3. Remote Monitoring
3.4.1.4. Data Collection and Analysis

3.3.2. Advantages and Disadvantages of Virtual Clinical Trials

3.4. Emerging Trends in Clinical Drug Development
3.4.1. Innovative Trial Designs
3.4.2. Real-world Evidence
3.4.3. Patient Centricity
3.4.4. Big Data Analytics
3.4.5. Blockchain Technology
3.5. Future Perspectives

4. VIRTUAL CLINICAL TRIAL SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Virtual Clinical Trial Service Providers: Overall Market Overview
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography
4.2.4. Analysis by Type of Service Offered

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Cambridge Cognition
5.2.1. Company Overview
5.2.2. Technology Overview
5.2.3. Recent Developments and Future Outlook

5.3. Center Point Clinical Services
5.3.1. Company Overview
5.3.2. Technology Overview
5.3.3. Recent Developments and Future Outlook

5.4. eClinicalHealth
5.4.1. Company Overview
5.4.2. Technology Overview
5.4.3. Recent Developments and Future Outlook

5.5. IQVIA
5.5.1. Company Overview
5.5.2. Technology Overview
5.5.3. Recent Developments and Future Outlook

5.6. Mytrus (Medidata Solutions)
5.6.1. Company Overview
5.6.2. Technology Overview
5.6.3. Recent Developments and Future Outlook
5.7. PanAmerican Clinical Research
5.7.1. Company Overview
5.7.2. Technology Overview
5.7.3. Recent Developments and Future Outlook

5.8. Science 37
5.8.1. Company Overview
5.8.2. Technology Overview
5.8.3. Recent Developments and Future Outlook

5.9. VirTrial
5.9.1. Company Overview
5.9.2. Technology Overview
5.9.3. Recent Developments and Future Outlook

6. CASE STUDY: VIRTUAL CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA PLAYERS
6.1. Chapter Overview
6.2. Virtual Clinical Trial-Related Initiatives of Big Pharma Players
6.2.1. Pfizer
6.2.1.1. Initial Approach and Key Learnings
6.2.1.2. Future Perspective

6.2.2. Johnson & Johnson
6.2.2.1. Initial Approach and Key Learnings
6.2.2.2. Future Perspective

6.2.3. Sanofi
6.2.3.1. Initial Approach and Key Learnings
6.2.3.2. Future Perspective

6.2.4. Novartis
6.2.4.1. Initial Approach and Key Learnings
6.2.4.2. Future Perspective

6.2.5. GlaxoSmithKline
6.2.5.1. Initial Approach and Key Learnings
6.2.5.2. Future Perspective

6.2.6. Amgen
6.2.6.1. Initial Approach and Key Learnings
6.2.6.2. Future Perspective

6.2.7. AstraZeneca
6.2.7.1. Initial Approach and Key Learnings
6.2.7.2. Future Perspective

7. CASE STUDY: TRADITIONAL VERSUS VIRTUAL CRO
7.1. Chapter Overview
7.2. Comparison between Traditional and Virtual CROs
7.3. Key Attributes of a Virtual CRO
7.4. The Virtual Operating Model
7.5. Concluding Remarks

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Virtual Clinical Trial Service Providers: Funding and Investment Analysis
8.3.1. Analysis by Year of Investment
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Most Active Players
8.3.5. Most Active Investors
8.4. Concluding Remarks

9. PARTNERSHIPS & COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Virtual Clinical Trial Service Providers: Partnership and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Focus Area Mentioned in Agreement
9.3.4. Analysis by Target Therapeutic Area Mentioned in Agreement
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Geographical Analysis
9.3.9. Intercontinental and Intracontinental Agreements

10. COVID-19 IMPACT
10.1. Chapter Overview
10.2. Impact of COVID-19 on Clinical Trials
10.3. Impact on Future Opportunity for Virtual Clinical Trials Service Providers

11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Virtual Clinical Trials: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Phase
11.3.3. Analysis by Trial Status
11.3.4. Analysis by Trial Design
11.3.5. Analysis by Type of Sponsor
11.3.6. Analysis by Target Therapeutic Area
11.3.7. Geographical Analysis by Number of Registered Trials
11.3.8. Geographical Analysis by Number of Patients Enrolled

12. MARKET OPPORTUNITY ASSESSMENT
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2020-2050
12.3.1. Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Therapeutic Area
12.3.2. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by End-user
12.3.3. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Trial Phase
12.3.4. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Geography

12.4. Virtual Clinical Trial Services Market in North America, 2020-2050
12.4.1. Virtual Clinical Trial Services Market in North America: Distribution by Therapeutic Area, 2020-2050
12.4.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050
12.4.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies

12.4.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050
12.4.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies

12.4.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050
12.4.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies

12.4.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050
12.4.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies

12.4.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050
12.4.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies

12.4.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050
12.4.6.1.1. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies
12.4.6.1.2. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies
12.4.6.1.3. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies
12.4.6.1.4. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies
12.4.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in North America, 2020-2050
12.4.7.1.1. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies
12.4.7.1.2. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies
12.4.7.1.3. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies
12.4.7.1.4. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies

12.5. Virtual Clinical Trial Services Market in Europe, 2020-2050
12.5.1. Virtual Clinical Trial Services Market in Europe: Distribution by Therapeutic Area, 2020-2050
12.5.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050
12.5.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies

12.5.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050
12.5.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies

12.5.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050
12.5.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies

12.5.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050
12.5.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies

12.5.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050
12.5.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies

12.5.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050
12.5.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies
12.5.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies
12.5.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies

12.5.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050
12.5.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies
12.5.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies
12.5.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies
12.5.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies

12.6. Virtual Clinical Trial Services Market in Asia-Pacific, 2020-2050
12.6.1. Virtual Clinical Trial Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2020-2050
12.6.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050
12.6.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

12.6.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050
12.6.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

12.6.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050
12.6.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

12.6.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050
12.6.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

12.6.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050
12.6.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies

12.6.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050
12.6.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies
12.6.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050
12.6.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies
12.6.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies
12.6.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies
12.6.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies

12.7. Virtual Clinical Trial Services Market in Rest of the World, 2020-2050
12.7.1. Virtual Clinical Trial Services Market in Rest of the World: Distribution by Therapeutic Area, 2020-2050
12.7.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050
12.7.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

12.7.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050
12.7.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

12.7.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050
12.7.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

12.7.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050
12.7.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

12.7.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050
12.7.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

12.7.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050
12.7.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies

12.7.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050
12.7.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies
12.7.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies
12.7.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies
12.7.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies

13. CONCLUSION

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. ConsilX
14.2.1. Interview Transcript: Himanshu Verma, Founder and Chief Executive Officer, ConsilX & Rajesh Jain, Co-Founder, ConsilX

14.3. EmpiraMed
14.3.1. Interview Transcript: Greg Erman, President and Chief Executive Officer, EmpiraMed

14.4. Andaman7
14.4.1. Interview Transcript: Phillipe Lemmens, Chief Operating Officer, Andaman7

14.5. uMotif
14.5.1. Interview Transcript: Jonathan Moshinsky, Head of Market Strategy, uMotif

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Existing Constraints in Clinical Research
Figure 3.2 Drug Development Costs: Historical Trend (USD Million)
Figure 3.3 Virtual Trial Model
Figure 3.4 Difference between Umbrella Trial and Basket Trial Designs
Figure 3.5 Process of Generating Evidence from Real World Data
Figure 3.6 Patient Centric Approach to Clinical Trials
Figure 3.7 Role of Big Data in Clinical Research
Figure 4.1 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment
Figure 4.2 Virtual Clinical Trial Service Providers: Distribution by Company Size
Figure 4.3 Virtual Clinical Trial Service Providers: Distribution by Location of Headquarters
Figure 4.4 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment and Company Size
Figure 4.5 Virtual Clinical Trial Service Providers: Distribution by Type of Service Offered
Figure 4.6 Virtual Clinical Trial Service Providers: Distribution by Company Size and Type of Service Offered
Figure 4.7 Virtual Clinical Trial Service Providers: Distribution by Number of Services Offered
Figure 5.1 Cambridge Cognition: Annual Revenues, 2016-H1 2020 (GBP Million)
Figure 5.2 IQVIA: Annual Revenues, 2017-2019 (USD Billion)
Figure 6.1 Virtual Clinical trial related Initiatives of Big Pharma Players: Timeline of Events
Figure 7.1 Key Attributes of Virtual CROs
Figure 7.2 Transition from Traditional CRO to Virtual CRO
Figure 8.1 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2020
Figure 8.2 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2020 (USD Million)
Figure 8.3 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2014-2020
Figure 8.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2014-2020 (USD Million)
Figure 8.5 Funding and Investment Analysis: Most Active Players, 2014-2020 (USD Million)
Figure 8.6 Funding and Investment Analysis: Most Active Investors
Figure 8.7 Funding and Investment Analysis: Distribution by Geography
Figure 8.8 Funding and Investment Analysis: Concluding Remarks
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2014-2020
Figure 9.4 Partnerships and Collaborations: Distribution by Focus Area Mentioned in the Agreement
Figure 9.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 9.6 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 9.7 Partnerships and Collaborations: Most Active Players
Figure 9.8 Partnership and Collaborations: Regional Distribution
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 COVID-19 Impact on Clinical Research
Figure 10.2 Virtual Clinical Trial Service Providers Market, 2020-2050: COVID Impact Scenario (USD Billion)
Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.4 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 11.5 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 11.6 Clinical Trial Analysis: Distribution by Target Indication
Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
Figure 11.8 Clinical Trial Analysis: Most Active Players
Figure 11.9 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Figure 11.10 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Figure 11.11 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Figure 12.1 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050 (USD Billion)
Figure 12.2 Virtual Clinical Trial Service Providers Market Opportunity, 2020 and 2050: Distribution by Therapeutic Area (USD Billion)
Figure 12.3 Virtual Clinical Trial Service Providers Market Opportunity, 2020 and 2050: Distribution by Phase of Development (USD Billion)
Figure 12.4 Virtual Clinical Trial Service Providers Market Opportunity, 2020 and 2050: Distribution by Geography (USD Billion)
Figure 12.5 Virtual Clinical Trial Services Market in North America, 2020-2050 (USD Billion)
Figure 12.6 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050 (USD Million)
Figure 12.7 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.8 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.9 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.10 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.11 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050 (USD Million)
Figure 12.12 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.13 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.14 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.15 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.16 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050 (USD Million)
Figure 12.17 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.18 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.19 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.20 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.21 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050 (USD Million)
Figure 12.22 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.23 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.24 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.25 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.26 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050 (USD Million)
Figure 12.27 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.28 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.29 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.30 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.31 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050 (USD Million)
Figure 12.32 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.33 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.34 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.35 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.36 Virtual Clinical Trial Services Market for Other Therapeutic Areas in North America, 2020-2050 (USD Million)
Figure 12.37 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.38 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.39 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.40 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.41 Virtual Clinical Trial Services Market Opportunity in Europe, 2020-2050 (USD Billion)
Figure 12.42 Virtual Clinical Trial Services Market Opportunity for Cardiovascular Disorders in Europe, 2020-2050 (USD Million)
Figure 12.43 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.44 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.45 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.46 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.47 Virtual Clinical Trial Services Market Opportunity for Infectious Disorders in Europe, 2020-2050 (USD Million)
Figure 12.48 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.49 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.50 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.51 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.52 Virtual Clinical Trial Services Market Opportunity for Metabolic Disorders in Europe, 2020-2050 (USD Million)
Figure 12.53 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.54 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.55 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.56 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.57 Virtual Clinical Trial Services Market Opportunity for Neurological Disorders in Europe, 2020-2050 (USD Million)
Figure 12.58 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.59 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.60 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.61 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.62 Virtual Clinical Trial Services Market Opportunity for Oncological Disorders in Europe, 2020-2050 (USD Million)
Figure 12.63 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.64 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.65 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.66 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.67 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in Europe, 2020-2050 (USD Million)
Figure 12.68 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.69 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.70 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.71 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.72 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in Europe, 2020-2050 (USD Billion)
Figure 12.73 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.74 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.75 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.76 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.77 Virtual Clinical Trial Services Market Opportunity in Asia Pacific 2020-2050 (USD Billion)
Figure 12.78 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.79 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.80 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.81 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.82 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.83 Virtual Clinical Trial Service Providers Market Opportunity for Infectious Disorders in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.84 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.85 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.86 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.87 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.88 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.89 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.90 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.91 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.92 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.93 Virtual Clinical Trial Service Providers Market Opportunity for Neurological Disorders in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.94 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.95 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.96 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.97 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.98 Virtual Clinical Trial Services Market Opportunity for Oncological Disorders in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.99 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.100 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.101 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.102 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.103 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.104 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.105 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.106 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.107 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.108 Virtual Clinical Trial Service Providers Market Opportunity for Other Therapeutic Areas in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.109 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.110 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.111 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.112 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.113 Virtual Clinical Trial Services Market Opportunity in Rest of the World, 2020-2050 (USD Million)
Figure 12.114 Virtual Clinical Trial Service Market for Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
Figure 12.115 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.116 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.117 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.118 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.119 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Figure 12.120 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.121 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.122 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.123 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.124 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Figure 12.125 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.126 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.127 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.128 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.129 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Figure 12.130 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.131 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.132 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.133 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.134 Virtual Clinical Trial Service Providers Market Opportunity for Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Figure 12.135 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.136 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.137 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.138 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.139 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Figure 12.140 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.141 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.142 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.143 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.144 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Figure 12.145 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.146 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.147 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.148 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 13.1 Concluding Remarks: Current Market Landscape
Figure 13.2 Concluding Remarks: Key Application Areas
Figure 13.3 Concluding Remarks: Partnerships and Collaborations
Figure 13.4 Concluding Remarks: Clinical Trial Analysis
Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Virtual Clinical Trial Service Providers: List of Companies
Table 4.2 Virtual Clinical Trial Service Providers: Type of Service Offered
Table 5.1 Leading Virtual Clinical Trial Service Providers
Table 5.2 Cambridge Cognition: Company Snapshot
Table 5.3 Cambridge Cognition: Recent Developments and Future Outlook
Table 5.4 Center Point Clinical Services: Company Snapshot
Table 5.5 Center Point Clinical Services: Recent Developments and Future Outlook
Table 5.6 eClinicalHealth: Company Snapshot
Table 5.7 eClinicalHealth: Recent Developments and Future Outlook
Table 5.8 IQVIA: Company Snapshot
Table 5.9 IQVIA: Recent Developments and Future Outlook
Table 5.10 Mytrus (Medidata Solutions): Company Snapshot
Table 5.11 Mytrus (Medidata Solutions): Recent Developments and Future Outlook
Table 5.12 PanAmerican Clinical Research: Company Snapshot
Table 5.13 Science 37: Company Snapshot
Table 5.14 Science 37: Recent Developments and Future Outlook
Table 5.15 VirTrial: Company Snapshot
Table 5.16 VirTrial: Recent Developments and Future Outlook
Table 6.1 Initiatives in Virtual Trials Domain: Big Pharma Players
Table 6.2 Virtual Clinical Trial Sponsors: List of Pharma Players
Table 7.1 Traditional Trials versus Virtual Trials
Table 8.1 Virtual Clinical Trial Services Market: Funding and Investments, 2014-2020
Table 8.2 Funding and Investment Analysis: Summary of Investments
Table 9.1 Virtual Clinical Trial Service Providers: Partnership and Collaborations, 2014-2020
Table 15.1 Drug Development Costs: Historical Trend (USD Million)
Table 15.2 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment
Table 15.3 Virtual Clinical Trial Service Providers: Distribution by Company Size
Table 15.4 Virtual Clinical Trial Service Providers: Distribution by Location of Headquarters
Table 15.5 Virtual Clinical Trial Service Providers: Distribution by Type of Services Offered
Table 15.6 Cambridge Cognition: Annual Revenues, 2016-H1 2020 (GBP Million)
Table 15.7 IQVIA: Annual Revenues, 2017-2019 (USD Billion)
Table 15.8 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2020
Table 15.9 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2020 (USD Million)
Table 15.10 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2020
Table 15.11 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2014-2020 (USD Million)
Table 15.12 Funding and Investment Analysis: Most Active Players, 2014-2020 (USD Million)
Table 15.13 Funding and Investment Analysis: Most Active Investors, 2014-2020
Table 15.14 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2020
Table 15.15 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.16 Partnerships and Collaborations: Distribution by Focus Area Mentioned in Agreement
Table 15.17 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 15.18 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 15.19 Partnerships and Collaborations: Most Active Players
Table 15.20 Partnership and Collaborations: Country-wise Distribution
Table 15.21 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 15.22 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year
Table 15.23 Clinical Trial Analysis: Distribution by Trial Status
Table 15.24 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 15.25 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 15.26 Clinical Trial Analysis: Distribution by Target Indication
Table 15.27 Clinical Trial Analysis: Distribution by Study Design
Table 15.28 Clinical Trial Analysis: Most Active Players
Table 15.29 Global Virtual Clinical Trial Service Providers Market, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
Table 15.30 Virtual Clinical Trial Service Providers Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2020, 2035 and 2050 (USD Million)
Table 15.31 Virtual Clinical Trial Service Providers Market: Distribution by Phase of Development, Conservative, Base and Optimistic Scenarios, 2020, 2035 and 2050 (USD Million)
Table 15.32 Virtual Clinical Trial Service Providers Market: Distribution by Geography, Conservative, Base and Optimistic Scenarios, 2020, 2035 and 2050 (USD Million)
Table 15.33 Virtual Clinical Trial Service Providers Market Opportunity in North America, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
Table 15.34 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050 (USD Million)
Table 15.35 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.36 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.37 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.38 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.39 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050 (USD Million)
Table 15.40 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.41 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.42 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.43 Virtual Clinical Trial Services Market for CNS Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.44 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050 (USD Million)
Table 15.45 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.46 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.47 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.48 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.49 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050 (USD Million)
Table 15.50 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.51 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.52 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.53 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.54 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050 (USD Million)
Table 15.55 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.56 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.57 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.58 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.59 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050 (USD Million)
Table 15.60 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.61 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.62 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.63 Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.64 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050 (USD Million)
Table 15.65 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.66 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.67 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.68 Virtual Clinical Trial Services Market for Other Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.69 Virtual Clinical Trial Service Providers Market Opportunity in Europe, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
Table 15.70 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050 (USD Million)
Table 15.71 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.72 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.73 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.74 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.75 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050 (USD Million)
Table 15.76 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.77 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.78 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.79 Virtual Clinical Trial Services Market for CNS Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.80 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050 (USD Million)
Table 15.81 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.82 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.83 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.84 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.85 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050 (USD Million)
Table 15.86 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.87 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.88 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.89 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.90 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050 (USD Million)
Table 15.91 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.92 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.93 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.94 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.95 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050 (USD Million)
Table 15.96 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.97 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.98 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.99 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.100 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050 (USD Million)
Table 15.101 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.102 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.103 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.104 Virtual Clinical Trial Services Market for Other Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.105 Virtual Clinical Trial Service Providers Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
Table 15.106 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050 (USD Million)
Table 15.107 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.108 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.109 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.110 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.111 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050 (USD Million)
Table 15.112 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.113 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.114 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.115 Virtual Clinical Trial Services Market for CNS Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.116 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050 (USD Million)
Table 15.117 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.118 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.119 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.120 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.121 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050 (USD Million)
Table 15.122 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.123 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.124 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.125 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.126 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050 (USD Million)
Table 15.127 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.128 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.129 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.130 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.131 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050 (USD Million)
Table 15.132 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.133 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.134 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.135 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.136 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050 (USD Million)
Table 15.137 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.138 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.139 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.140 Virtual Clinical Trial Services Market for Other Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.141 Virtual Clinical Trial Service Providers Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2050 (USD Billion)
Table 15.142 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.143 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.144 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.145 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.146 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.147 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.148 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.149 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.150 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.151 Virtual Clinical Trial Services Market for CNS Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.152 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.153 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.154 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.155 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.156 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.157 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.158 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.159 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.160 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.161 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.162 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.163 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.164 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.165 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.166 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.167 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.168 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.169 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.170 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.171 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.172 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.173 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.174 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.175 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.176 Virtual Clinical Trial Services Market for Other Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)

List Of Companies

The following companies and organizations have been included in the report:

Academic Medical Center Amsterdam
ACRP
Advarra
AiCure
Alacris Theranostics
AliveCor
Andaman7
Aparito
AstraZeneca
Atlantic General Hospital
BARDA
BetterLife
BioIntelliSense
Boehringer Ingelheim
CAIMED
Cambridge Cognition
Cancer Hope Network
Castor
Center Point Clinical Services
City of Hope Medical Center
Click Therapeutics
ClinCloud Tech
Clinerion
Clinical Ink
Clinical Trials Transformation Initiative
ClinOne
ConsilX
Covance
Covance
Cquentia
Ctrl Group
Datavant
Delve Health
Dreem
DxTerity
eClinicalHealth
Elektra Labs
Eli Lilly
EmpiraMed
ERT
Evidation
Foundation Medicine
GI Partners
Harte Group
Healint
i3 Consult
iClinical
IDD Research
IQVIA
ISBX
Jeeva Informatics
Kinsights
KiwiTech
LabCorp
LabCorp
Medable
Medikit
Medocity
Medpoint Digital
monARC Bionetworks
MRN
Myovant Sciences
Medidata Solutions
Novartis
ObvioHealth
Otsuka Pharmaceutical
PanAmerican Clinical Research
PPMD
Redox
Roivant
Sage Bionetworks
Sanofi
Sanofi
Sarcoma Alliance
Science 37
Signant Health
SnapIoT
Studies&Me
Synevo Central Labs
Synexus
THREAD Research
Transparency Life Sciences
UBC
UCB
Unnamed CRO
Unnamed Pharmaceutiical Company
Virtrial
VisualDx
Vsee
Wellcome Trust
xCures

PRICING DETAILS

Single-User License USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

One Location Site License USD 7,999

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

Department License USD 10,599

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

Enterprise License USD 15,999

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

Example Insights

Overview

Scope of the Report

Contents

Chapter Outlines

Tables Of Contents

List Of Figures

List Of Tables

List Of Companies

Single-User License USD 5,899

One Location Site License USD 7,999

Department License USD 10,599

Enterprise License USD 15,999

BLOGS

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Novel Cell Cytometers: Need of the Hour

Market Insights Reports

Indication Specific Reports

Virtual Clinical Trials

Example Insights

Overview

Scope of the Report

Contents

Chapter Outlines

Tables Of Contents

List Of Figures

List Of Tables

List Of Companies

Single-User License USD 5,899

One Location Site License USD 7,999

Department License USD 10,599

Enterprise License USD 15,999

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Novel Cell Cytometers: Need of the Hour

This site uses cookies for better browsing experienceAccept